TITLE

Sorting Through the Science on Marijuana: Facts, Fallacies, and Implications for Legalization

AUTHOR(S)
Danovitch, Itai
PUB. DATE
January 2012
SOURCE
McGeorge Law Review;Jan2012, Vol. 43 Issue 1, p91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses various issues related to the legalization of marijuana in the U.S. concerning its biological and medical characteristics, and its merits and demerits. It takes account of a situation that might arise due to the U.S. Food and Drug Administration's (FDA) process of examining whether a substance should be legal for medicinal or non-medicinal consumption regarding marijuana. It further elaborates on the evidences that support the medical syndrome of addiction of marijuana. It mentions that some believe addiction to marijuana. does not exist.
ACCESSION #
86195423

 

Related Articles

  • Medical Marijuana: A Study of Unintended Consequences. Caplan, Gerald // McGeorge Law Review;Jan2012, Vol. 43 Issue 1, p127 

    An essay is presented on examining the effects of the implementation of medical marijuana legislation in multiple states of the U.S. It elaborates on whether the humanitarian objectives of legalizing medical marijuana have been achieved after providing access to marijuana to those who will get...

  • Since 1989 Trying to Understand Brazil. Buarque, Cristovam // Brazzil;Mar2014, p1 

    The article focuses on the petition signed by 22000 people in favor of regulating marijuana for recreational and medicinal use in Brazil. Topics discussed include the motto "Don't fool around with drugs," questions about the relationship between marijuana and violence, and questions about...

  • Marijuana Goes Legit, but the Future of Research Is Hazy. MARRIS, EMMA // Discover;Jan/Feb2015, Vol. 36 Issue 1, p17 

    The article focuses on the lack of studies on the long-term effects of marijuana use in 2014. Topics include the change in public opinion of marijuana use, the safety of marijuana use, and the legalization of recreational marijuana in Alaska, Oregon, Washington, and Colorado. Information is...

  • OxyContin patent expires, fears of abuse return. DEARMENT, ALARIC // Drug Store News;5/13/2013, Vol. 35 Issue 5, p53 

    The article reports on the implications of the expiration of Pfizer's OxyContin patent in April 16, 2013. It says that the drug has become a drug of abuse since its U.S. Food and Drug Administration approval in 1995. It says that the expiration of the said drug renews fears of it becoming...

  • Withdrawing for Safety. Sampson, Kyle // Contract Pharma;Sep2013, Vol. 15 Issue 7, p18 

    The article discusses how the U.S. Food and Drug Administration (FDA) determines the withdrawal of a drug from sale for safety reasons. It mentions that withdrawal of the drug from involves its removal from the agency's Orange Book. It notes that the agency refuses to approve any abbreviated new...

  • Excess Marks the Spot.  // Time;9/27/1982, Vol. 120 Issue 13, p87 

    The article reports on the claim of the U.S. Food and Drug Administration (FDA) about the increasing number of people and organization which abuse drug use. It states that the claim was announced after the FDA found out that only three drugs out of 96 received approval in 1981. The article also...

  • Pharmacyclics files cancer drug over protest.  // PharmaWatch: Biotechnology;May2007, Vol. 6 Issue 5, p8 

    The article reports that Pharmacyclics Inc. has filed protest on the disagreement with U.S. Food and Drug Administration (FDA) over the acceptability of a submission of their drug application for the cancer drug Xcytrin. FDA claimed the application did not get an approval because it failed to...

  • FDA okays only 25 new biotech drugs in 2013. SURESH, NARAYANAN // BioSpectrum;Jul2014, Vol. 12 Issue 7, p90 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved 25 new drugs wherein two of the drugs have an annual sales of $1 billion such as Ibruvica and Pomalyst. It states that both drugs are anti-cancer drugs like Ibruvica, treat mantle cell lymphoma cancer condition and...

  • Breakthrough programme turns two. Mullard, Asher // Nature Reviews Drug Discovery;Dec2014, Vol. 13 Issue 12, p873 

    The article discusses the publicly-disclosed breakthrough of the designations for small molecules, mono-and bispecific antibodies, engineered T cells, stem cells and vaccines. It states that the U.S. Food and Drug Administration (FDA) has approved drugs with breakthrough designations that use to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics